NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Et studie fra North Carolina School of Medicine viser tegn på, at Novo Nordisk-medicinen Ozempic kan have gavnlig effekt på ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Det kører tilsyneladende for DSB, som sidste år landede et overskud før skat på 675 millioner kroner, hvilket er 250 ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Due to the size of their presence and investment in the United States, Novo Nordisk CEO Lars Fruergaard Jørgensen isn’t worried about Trump’s tariff threats.“We have good standing in relation to the ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression. According to ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...